BREAST-FEEDING AND MATERNAL-DONOR RENAL-ALLOGRAFTS - POSSIBLY THE ORIGINAL DONOR-SPECIFIC TRANSFUSION

BREAST-FEEDING AND MATERNAL-DONOR RENAL-ALLOGRAFTS - POSSIBLY THE ORIGINAL DONOR-SPECIFIC TRANSFUSION
复制标题

DOI:
10.1097/00007890-198404000-00004
复制
发表时间:
1984-01-01
期刊:
影响因子:
6.2
通讯作者:
BEER, AE
BEER, AE
中科院分区:
医学2区
文献类型:
--
作者:
CAMPBELL, DA;LORBER, MI;BEER, AE

文献摘要

被引文献

相似文献

母乳中存在大量的母体淋巴细胞。为了确定婴儿在母乳喂养过程中接触母体淋巴细胞是否会影响患者随后接受母体供者相关肾移植的反应性,对55名接受初级母体供体肾移植的患者的移植后过程进行了研究。27名受试者在婴儿时期接受母乳喂养,28名受试者没有接受母乳喂养。母乳喂养史与移植后更有利的疗程有关,通过移植后第一年内没有排斥反应的患者的百分比来衡量(P.1toreq。0.006)。接受母乳喂养的受者一年的移植物功能好转率为82%;这在统计学上明显好于非母乳喂养受者的57%(P。0.05)。当在5年的时间间隔内评估结果时,组间差异的统计学意义没有达到。当评估接受父系供者移植的较小一组患者时,母乳喂养的和非母乳喂养的受者之间的差异并不明显。根据这些观察,可以得出结论,婴儿时期的母乳喂养过程可能会对随后的母体-供者相关肾移植的受者产生可测量的免疫学益处。
Large numbers of maternal lymphocytes are present in breast milk. To determine whether exposure of an infant to maternal lymphocytes during the process of breast feeding would have an effect on the subsequent reactivity of a patient to a maternal-donor related renal transplant, the posttransplant course of 55 patients who had received a primary maternal-donor transplant was studied. Twenty-seven recipients had been breast-fed during infancy and 28 recipients had not been breast-fed. A history of breast feeding was associated with a more favorable posttransplant course as measured by the percentage of patients who had no rejection episodes during the 1st posttransplant year (P .ltoreq. 0.006). The 1-yr graft function rate for breast-fed recipients was 82%; this was statistically significantly better than the 57% measured for non-breast-fed recipients (P .ltoreq. 0.05). Statistical significance of differences between groups was not attained when results were evaluated over a 5-yr interval. A difference between breast-fed and non-breast-fed recipients was not apparent when a somewhat smaller group of patients who had received a paternal donor transplant was evaluated. From these observations it may be concluded that the process of breast feeding during infancy may result in a measurable immunologic benefit to the recipient of a subsequent maternal-donor related renal transplant.